Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China
Table 3
Multivariate Cox proportional hazard regression model for analyzing the independent prognostic factors in the construction cohort.
Subject characteristics
B
SE
Wald
value
HR
HR 95% CI
Age
18–45
0.332
0.847
1.00
Ref
46–55
0.087
0.192
0.206
0.650
1.09
0.75–1.59
>55
−0.023
0.224
0.010
0.918
0.98
0.63–1.52
ABO blood type
A type
5.191
0.158
1.00
Ref
B type
0.315
0.204
2.376
0.123
1.37
0.92–2.04
AB type
0.495
0.265
3.503
0.061
1.64
0.98–2.76
O type
0.047
0.231
0.042
0.837
1.05
0.67–1.65
CA153
0–25 U/ml
1.00
Ref
>25 U/ml
−0.268
0.189
2.005
0.157
0.77
0.53–1.11
ALP
50–135 U/L
7.448
0.024
1.00
Ref
<50 U/L
0.090
0.290
0.097
0.756
1.09
0.62–1.93
>135 U/L
0.536
0.197
7.448
0.006
1.71
1.16–2.51
Grade
I-II
1.00
Ref
III
0.124
0.197
0.392
0.531
1.13
0.77–1.67
Lymph node metastasis
Yes
1.00
Ref
No
−0.075
0.209
0.129
0.719
0.93
0.62–1.40
ER status
Positive
1.00
Ref
Negative
−0.066
0.214
0.094
0.759
0.94
0.62–1.42
PR status
Positive
1.00
Ref
Negative
0.289
0.191
2.303
0.129
1.34
0.92–1.94
Her-2 status
Positive
1.00
Ref
Negative
−0.207
0.197
1.106
0.293
0.81
0.55–1.20
Ki-67 status
Positive
1.00
Ref
Negative
0.341
0.207
2.714
0.099
1.41
0.94–2.11
Surgery for BC
Yes
1.00
Ref
No
0.786
0.267
8.655
0.003
2.19
1.30–3.70
Chemotherapy
No
1.00
Ref
Yes
−0.373
0.406
0.845
0.358
0.69
0.31–1.53
Endocrinotherapy
No
1.00
Ref
Yes
−0.080
0.190
0.178
0.673
0.92
0.64–1.34
Time of BM
MBM
1.00
Ref
SBM
0.684
0.247
7.646
0.006
1.98
1.22–3.22
Performance of BPs
No
1.00
Ref
Yes
−0.308
0.200
2.364
0.124
0.74
0.50–1.09
Liver metastasis
No
1.00
Ref
Yes
0.521
0.175
8.872
0.003
1.68
1.20–2.37
Lung metastasis
No
1.00
Ref
Yes
−0.216
0.165
1.725
0.189
0.81
0.58–1.11
Other organs metastasis
No
1.00
Ref
Yes
−0.288
0.197
2.139
0.144
0.75
0.51–1.10
CA153: carbohydrate antigen 153; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.
